STATICH Antiplatelets: Underpowered Trial Leaves ICH Restart Dilemma Open

This prematurely terminated Scandinavian randomized trial provides directional but statistically inconclusive data on restarting antiplatelet therapy after intracerebral hemorrhage, relevant to neurology and stroke pharmacists managing secondary prevention decisions.

📅 Journal publication: Aug 2026 (online Jun 18, 2026) · Last updated: Oct 12, 2026

aspirinacetylsalicylic acidantiplatelet agentsintracerebral hemorrhagesecondary preventionischemic strokerandomized controlled trialSTATICHneuropharmacology Anticoagulation / Hematology

Also in Neurology / Neuropharmacology

Background Information

Restarting antiplatelets after ICH: Safe or risky?

Deciding when to restart antiplatelet therapy after intracerebral hemorrhage (ICH) is a clinically challenging decision. The STATICH trial evaluated the safety and outcomes of restarting antiplatelet therapy after ICH, showing no significant increase in recurrent bleeding risk. This study suggests restarting antiplatelets after ICH may be safe, but further evidence is needed to confirm practice changes. Antiplatelet therapy may be restarted safely after ICH, but caution is advised.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Eilertsen H, Larsen KT, Forfang E, Pennlert J, Glader EL, Kruuse C, Wester P, Ihle-Hansen H, Carlsson M, Lied-Herland T, Benth JŠ, Ihle-Hansen H, Seljeseth Y, Folke MN, Al-Shahi Salman R, Wyller TB, Ronning OM, Sandset EC, all STATICH Investigators

Citation: Eilertsen H, Larsen KT, Forfang E, et al. Study of Antithrombotic Treatment After Intracerebral Haemorrhage-Antiplatelets: A Randomized Trial. Stroke. 2026;57(8):2287-2294. doi:10.1161/STROKEAHA.125.054990

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →